Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MB-dNPM1-TCR.1 |
Synonyms | |
Therapy Description |
Limited information is currently available on MB-dNPM1-TCR.1, a putative HLA-A*02:01-restricted T-cell receptor (TCR) T-cell therapy targeting mutant NPM1 (Sep 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MB-dNPM1-TCR.1 | MB-dNPM1TCR.1|MB-dNPM1 TCR.1 | Limited information is currently available on MB-dNPM1-TCR.1, a putative HLA-A*02:01-restricted T-cell receptor (TCR) T-cell therapy targeting mutant NPM1 (Sep 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06424340 | Phase Ib/II | MB-dNPM1-TCR.1 | MB-dNPM1-TCR.1 in Relapsed/Refractory AML | Recruiting | NLD | 0 |